Economic burden and current managed care challenges associated with hepatitis C

Area of Science:

• Hepatology
• Infectious Diseases
• Health Economics

Background:

• Hepatitis C virus (HCV) infection causes substantial morbidity, mortality, and economic impact.
• HCV remains underdiagnosed and undertreated, with standard therapies achieving sustained virological response in less than 50% of patients.
• Emerging therapies offer improved outcomes but incur higher treatment costs.

Purpose of the Study:

• To emphasize the importance of understanding the cost-effectiveness of hepatitis C virus (HCV) treatment.
• To highlight that the economic burden of HCV extends beyond direct treatment expenses.
• To inform clinicians, patients, and managed care professionals about optimizing HCV management.

Main Methods:

• This study reviews the economic implications of HCV treatment and management.
• Analysis focuses on the cost-effectiveness of various therapeutic approaches.
• The impact of adherence and care delivery on long-term outcomes is considered.

Main Results:

• Standard HCV therapies have limited efficacy, necessitating consideration of newer, more expensive options.
• Improved patient adherence and effective care delivery can mitigate long-term costs.
• Cost-effective management strategies can reduce complications like hospitalization, liver transplantation, and mortality.

Conclusions:

• Understanding the cost-effectiveness of HCV treatment is vital for all stakeholders.
• Optimizing care delivery and patient adherence are key to managing the economic burden of HCV.
• Effective HCV management can lead to significant reductions in long-term disease-related complications and associated costs.